Alectinib
Generic Details
Generic Name
Alectinib
Other Names
- Alecensa
Drug Class
- Antineoplastic agent
- Tyrosine kinase inhibitor
Chemical Formula
C30H34N4O2
Molecular Weight
482.62 g/mol
Mechanism of Action
- Inhibits ALK (Anaplastic Lymphoma Kinase) and ROS1 receptor tyrosine kinases
Indications
- Treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC)
Common Dosage Forms
- Capsules
Typical Dosage
- 600 mg orally twice daily with food
Pediatric Dosage
- Safety and efficacy not established in children
Geriatric Dosage
- No dose adjustment necessary based on age alone
Side Effects
- Fatigue
- Edema
- Myalgia
- Anemia
- Nausea
- Constipation
Contraindications
- Hypersensitivity to alectinib
Pregnancy Category
- Category D - Positive evidence of risk
Lactation Safety
- Safety unknown, avoid breastfeeding during treatment
Drug Interactions
- Strong CYP3A inhibitors/inducers may alter alectinib levels
Overdose Symptoms
- Nausea
- Vomiting
- Bradycardia
Antidote for Overdose
- Supportive care and symptomatic treatment
Storage Conditions
- Store at room temperature away from moisture and heat
Pharmacokinetics
- Absorption: Well absorbed orally
- Distribution: Extensively distributed, crosses the blood-brain barrier
- Metabolism: Primarily hepatic via CYP3A4
- Excretion: Mainly in feces
Precautions
- Monitor for pulmonary symptoms
- Regular liver function tests
- Monitor for QT prolongation
Warnings
- Interstitial lung disease
- Bradycardia
- Hepatotoxicity
Others
- Patients should undergo regular eye exams due to potential vision changes